Welcome to our dedicated page for Dyne Therapeutics SEC filings (Ticker: DYN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Dyne Therapeutics, Inc. filings document regulatory disclosures for a clinical-stage neuromuscular disease company advancing FORCE platform programs. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary cash-resource disclosures, investor presentation materials, clinical and FDA-related updates, and other business highlights tied to Duchenne muscular dystrophy and myotonic dystrophy type 1 programs.
The company’s definitive proxy materials cover board structure, director elections, executive compensation, equity awards, stockholder voting matters and governance practices. Other filings address board appointments, non-employee director compensation arrangements and Nasdaq-related inducement equity awards.
Dyne Therapeutics director-affiliated entity reports small share sales under a pre-set plan. ForDyne B.V., an entity associated with director Dirk Kersten, sold 8,300 and 2,652 shares of Dyne Therapeutics common stock on April 21, 2026 and April 22, 2026 in open-market transactions at weighted average prices of about $20.01 and $20.00 per share, respectively, under a Rule 10b5-1 trading plan. After these trades, ForDyne continues to hold about 4,196,573 shares indirectly, and Kersten disclaims beneficial ownership beyond his pecuniary interest.